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Abstract
Background: In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, 
data on severe adverse events (SAEs) according to CD4 cell count are limited. We estimated the incidence of SAEs 
according to CD4 cell count and identify their risk factors in nevirapine-treated women.
Methods: All HIV-infected women who initiated nevirapine-containing regimen in the MTCT-Plus operational program 
in Abidjan, Côte d'Ivoire, were eligible for this study. Laboratory and clinical (rash) SAEs were classified as grade 3 and 4. 
Cox models were used to identify factors associated with the occurrence of SAEs.
Results: From August 2003 to October 2006, 290 women initiated a nevirapine-containing regimen at a median CD4 
cell count of 186 cells/mm3 (IQR 124-266). During a median follow-up on treatment of 25 months, the incidence of all 
SAEs was 19.5/100 patient-years. The 24-month probability of occurrence of hepatotoxicity or rash was not different 
between women with a CD4 cell count >250 cells/mm3 and women with a CD4 cell count ≤250 cells/mm3 (8.3% vs. 
9.9%, Log-rank test: p = 0.75). In a multivariate proportional hazard model, neither CD4 cell count >250 cells/mm3 at 
treatment initiation nor initiation NVP-based regimen initiated during pregnancy were associated with the occurrence 
of SAEs.
Conclusion: CD4 cell count >250 cells/mm3 was not associated with a higher risk of severe hepatotoxicity and/or rash, 
as well as initiation of ART during pregnancy. Pharmacovogilance data as well as meta-analysis on women receiving 
NVP in these settings are needed for better information about NVP toxicity.
Background
At the end of 2007, more than three million people were
receiving Highly Active Antiretroviral Therapy (HAART)
in resource-limited settings [1]. The first-line regimen
recommended by the World Health Organization
(WHO) in resource-limited includes two nucleoside
reverse transcriptase inhibitors (NRTI) with one non-
nucleoside reverse transcriptase inhibitor (NNRTI) [2].
Nevirapine (NVP) is the preferred NNRTI in first-line
antiretroviral regimens in pregnancy because of substan-
tial clinical experience with pregnant women and its
proven efficacy in reducing mother-to-child transmission
[3,4]. The most frequent adverse events of NVP are hepa-
totoxicity and cutaneous rash. Studies from developed
countries report an increased risk of severe hepatotoxic-
ity and cutaneous rash in women with CD4 count >250
cells/mm3 [5-9]. Based on these findings, WHO recom-
mends avoiding NVP in women, including pregnant
women, with CD4 counts between 250 and 350 cells/
mm3, or if no other options exist as it is often the case in
resource-limited settings, using it with caution and close
monitoring during the first 12 weeks of therapy [2,8].
Although some cases have been reported in pregnant
women, it is still not known whether pregnancy increases
the risk of the occurrence of hepatotoxicity or rash [9-11].
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In resource-limited settings, where NVP is widely used in
women and during pregnancy whatever the level of CD4,
there is little data on the occurence of hepatotoxicity and/
or rash according to CD4, and all except one study did
not find this association [12-16].
We hypothesize that HAART initiation among preg-
nant HIV-infected women or HIV-infected women with
CD4 count >250 cells/mm3 may be associated with an
increased frequency of SAEs. Thus, we estimated in the
MTCT-Plus program in Abidjan, Côte d'Ivoire, the inci-
dence rate of all severe adverse events (SAEs) according
to CD4 cell count and pregnancy status, especially hepa-
totoxicity and/or rash and investigated their risk factors
in women initiating NVP-based HAART.
Methods
Study design and setting
A prospective cohort study was conducted in Abidjan,
Côte d'Ivoire between August 2003 and October 2006
among women enrolled in the MTCT-Plus program,
which is built upon existing prevention of mother-to-
child transmission (PMTCT) services and provides HIV-
infected women, their partners, and their children, holis-
tic family care with unrestricted access to HAART for eli-
gible patients [17,18].
Study population
All HIV-infected women were included in this study if
they initiated NVP-based HAART according to the fol-
lowing eligibility criteria: WHO clinical stage 2 (until
December 2004) or stage 3 and CD4+ T lymphocytes
(CD4 cell count) <350 cells/mm3, or stage 4 regardless of
CD4 cell count, or CD4 cell count <200 cells/mm3. The
women had to meet one additional biological criterion
before initiating HAART: aminotransferase and/or
alaninetransferase levels no more than three times the
upper limit of the normal range. All women with a CD4
cell count <350 cells/mm3 were also prescribed co-tri-
moxazole prophylaxis. All women were ARV-naive with
the exception of prior PMTCT exposure.
Ethical aspects
The MTCT-Plus program was reviewed by the institu-
tional review board (IRB) from Columbia University in
2000 (principal sponsor) and was not considered a
research project but rather a demonstration program in
the context of the ARV roll-out. As an operational HIV
care and treatment program MTCT-Plus program was
exempted from review by the IRB from the Ministry of
health of Côte d'Ivoire.
Enrollment and follow-up
Maternal socio-demographic, clinical and biological
characteristics were recorded at enrollment in the pro-
gram and at initiation of HAART [18]. During weekly fol-
low-up visits for the first two months and monthly visits
thereafter, clinical signs and symptoms, drug intake, and
tolerance were assessed. Between scheduled visits,
women had free access to the study clinics for medical
problems. Total blood cell count (MaxM, Beckman-
Coulter, Miami, FL, USA), serum liver enzymes, and
serum creatinine were monitored according to the fol-
lowing schedules: in women starting HAART after deliv-
ery at baseline, month 1, and every three months
thereafter; in women starting HAART prepartum at
baseline, week 2, month 1, and monthly thereafter during
pregnancy. CD4 cell count were measured using a dual-
platform flow cytometry technique with an automated
blood cell counter (MaxM, BeckmanCoulter, Miami, FL,
USA), at the screening visit and then every six months.
Serology for hepatitis B was not routinely performed. All
blood samples were processed in the same laboratory.
Outcomes and definitions
The outcomes of interest were the occurrence of SAEs
defined as clinical and biological grade ¾ adverse events
according to the Agence Nationale de la Recherche sur le
Sida et les hepatites virales (ANRS) table for grading the
severity of adult adverse events [19]: at least one haemo-
globinaemia measurement <70 g/l, one neutrophil count
<750/mm3, one amino and/or alaninetransferase mea-
surement more than five times the upper limit of the nor-
mal range and any extended papulovesicular or oozing
eruption, palpable purpura (suggestive of vasculitis),
polymorphous erythaema, small-size cutaneous or
mucous ulcerations, any blistering cutaneous and/or
mucosal lesions (Lyell or Stevens-Johnson), febrile eryth-
rodermia, whether or not associated with other signs
indicative of hypersensitivity, cutaneous necrosis requir-
ing surgical excision. All SAEs were reported by clinicians
during follow-up visits and subsequently validated by two
expert clinicians. If the experts disagree, a third expert
was called upon to avoid misclassification and to validate
a final diagnosis.
Statistical analysis
Group comparisons used Student's t-test, non-paramet-
ric Mann-Whitney U test or variance analysis for contin-
uous variables, and the Chi2 test or Fisher's exact test for
categorical variables. The incidence rate of SAEs per 100
patient-months or years was estimated with its 95% confi-
dence interval (CI). The Log-Rank test was used to com-
pare the incidence rate between two groups. Univariable
and then multivariable Cox regression analyses were per-
formed to identify factors associated with the occurrence
of these SAEs. All factors associated with the outcomes at
a P value <0.25 were included in the multivariable analy-
sis. The CD4 cell count and WHO clinical stage at
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HAART initiation were kept in the final model. Adjusted
hazard ratios (aHR) and their 95% CI are reported with
two-sided p-values. All analyses were performed in
intent-to-treat and on treatment [20] with SAS software
version 9.1 (SAS Institute, Cary, NC, USA).
Results
Patients and follow-up
From August 2003 to October 2006, 530 women were
enrolled in MTCT-Plus and 290 (54.7%) women initiated
a NVP-containing regimen and were included in this
study. Their median age at HAART initiation was 29
years (inter-quartile range [IQR] 26-33) and median CD4
cell count was 186 cells/mm3 (IQR 124-266). Two-hun-
dred and two women (70%) initiated HAART with a CD4
cell count ≤250 cells/mm3, 130 (44.8%) were at WHO
clinical stage 3 or 4, 125 (43.0%) initiated HAART during
pregnancy, and 287 (99.0%) started co-trimoxazole. Dur-
ing a median follow-up on HAART of 25 months (IQR
14-30), seven women (2.4%) were lost to follow-up, seven
(2.4%) stopped HAART on their own initiative and 16
(5.5%) died. The baseline and follow-up characteristics of
these women are summarized in Table 1.
Antiretroviral therapy
The first-line HAART regimen was ZDV/3TC/NVP in
265 women (91.4%) and stavudine (d4T)/3TC/NVP in 25
women (8.6%). In this cohort, 153 women (52.8%) were
previously exposed to a PMTCT regimen during a previ-
ous pregnancy: short-course (sc) ZDV and lamivudine
plus single dose nevirapine (sdNVP) (n = 84), scZDV plus
sdNVP (n = 65) and scZDV alone (n = 2). The median
interval between exposure to PMTCT and initiation of
HAART was 22 months (IQR 13-21).
Incidence rate of severe adverse events
A total of 104 SAEs were reported in 88 women (30.3%)
as follows: neutropenia (n = 60; 20.7%), anaemia (n = 17;
5.9%), rash (n = 15; 5.2%), hepatotoxicity (n = 10; 3.4%),
headache and neuropathy (n = 1; 0.3%).
The overall incidence rate of SAEs was 19.5/100
patient-years (PY), (95% CI 15.9-23.4): 13.3/100 PY (95%
CI 10.3-16.8) for neutropenia, 3.8/100 PY (95% CI 2.2-
6.0) for anemia, 3.3/100 PY (95% CI 1.9-5.4) for rash, and
2.2/100 PY (95% CI 1.1-4.0) for hepatotoxicity. The
median delay between HAART initiation and occurrence
of all SAEs was 3.0 months (IQR 1-6). It was 6.0 months
(IQR 2.5-7.5) for neutropenia, 4.0 months (IQR 2-5) for
anemia, 2.5 months (IQR 1-11) for hepatotoxicity, and 1.0
month (IQR 1-3) for rash. The overall probability of
occurrence of SAEs was 17.0% (95% CI 13.1-21.9%) at
month-3, 29.7% (95% CI 24.6-35.6%) at month-12, 33.9%
(95% CI 28.4-40.2%) at month-24 (Figure 1).
Table 1: Baseline and follow-up characteristics of HIV-
infected women in the MTCT-Plus program (N = 290).
At initiation of treatment 




Exposed women to PMTCT
Exposed/no exposed, n 
(%)
153/137 (53/47)
Age, years, median [IQR] 29 [26-33]
>29 years 137 (47)
Body mass index, Kg/m2 [IQR] 22.3 [20.1-25.3]
>18.5 * 250 (86)





CD4 counts, cells/mm3 [IQR] 186 [124-266]
>250 88 (30)
Co-trimoxazole, n (%) 287 (99)








HAART regimen, n (%)
ZDV/3TC/NVP 265 (91)
d4T/3TC/NVP 25 (9)
Alanine aminotransferase, UI, 
median [IQR]
15 [11-24]




<32 IU/L* 235 (81)
Follow-up 
Cumulative, person-months 6388
Per patient, months, median 
[IQR]
25 [14-30]
Status on study termination
Dead, n (%) 16 (6)
Lost to follow-up, n (%) 7 (2)
Alive, n (%) 267 (92)
HAART: Highly active antiretroviral therapy; PMTCT: prevention 
to mother-to-child transmission; WHO: World Health 
Organization; IQR: interquartile range; ZDV: zidovudine; 3TC: 
lamivudine; NVP: nevirapine; d4T: stavudine; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; IU: 
International unity;
* upper limit of normal
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Among the 16 women who died, eight (50.0%) had a
history of SAEs. Table 2 describes the death cases. When
considering death or SAEs, the 12-month and 24-month
were 32.1% (95% CI 26.8-38.0%) and 36.6% (95% CI 30.9-
42.9%) respectively (Figure 1).
Severe adverse events and CD4 count at the initiation of 
treatment
The median CD4 cell count was 151 cells/mm3 (IQR 106-
190) for women who initiated HAART with a CD4 cell
count ≤250 cells/mm3 and 303 cells/mm3 (IQR 275-331)
for those who initiated HAART at >250 cells/mm3. Base-
line characteristics such as age, body mass index (BMI),
and WHO clinical stage were comparable between the
two groups except for the proportion of women who ini-
tiated HAART during pregnancy: in women with a CD4
cell count ≤250 cells/mm3, 47% initiated HAART while
pregnant vs. 34% in women with a CD4 cell count >250
cells/mm3 (p = 0.04). The 24-month probability of occur-
rence of rash or hepatotoxicity was not different between
women with a CD4 cell count >250 cells/mm3 and
women with a CD4 cell count ≤250 cells/mm3 (8.3% vs.
9.9%, Log-rank test: p = 0.75). Similarly, this 24-month
probability was not different between the two groups
when considering death and SAEs combined (27.0% vs.
40.7% respectively, Log-rank test, p = 0.08).
Severe adverse events and period of HAART initiation
The baseline characteristics such as age, BMI, WHO clin-
ical stage and CD4 cell count, were comparable between
the women who initiated HAART during pregnancy
(group 1) and those who did not (group 2). The median
interval between HAART initiation and delivery was 3.0
months (IQR 2-3) in women in group 1 and during this
period, the incidence rate was 3.4/100 patient-months
(IQR 1.7-6.1) for all SAEs and 1.6/100 patient-months
(IQR 0.5-3.6) for rash and/or hepatotoxicity. In women in
group 2, when restricting the analyses to the first three
months of follow-up after HAART initiation, the inci-
dence rate was 6.1/100 patient-months [IQR 4.1-8.6] for
all SAE and 2.5/100 patient-months [IQR 1.3-4.3] for rash
and/or hepatotoxicity. The 3-month probability of occur-
rence of rash or hepatotoxicity did not differ between
groups 1 and 2 (5.3% vs. 7.5%; Log-Rank test, p = 0.35)
(Figure 2).
Evolution of severe adverse events
One hundred and four SAEs were reported and led to a
change in treatment in 47 cases. NVP was switched to a
protease inhibitor secondary to grade 3 rash (n = 15) or
grade 3/4 liver toxicity (n = 4), or to EFV (n = 3) or aba-
cavir (n = 1) owing to grade 3/4 liver toxicity. For two
cases of hepatotoxicity, NVP was kept in the HAART reg-
imen because of a transient elevation of liver function
enzymes. Zidovudine was switched to stavudine owing to
grade 3/4 anaemia (n = 15), neutropenia (n = 7), and
headache (n = 1). The SAEs resolved after interruption of
co-trimoxazole for two cases of anaemia and 53 cases of
neutropenia. Stavudine was switched to abacavir for one
case of neuropathy.
Severe adverse events were reported in eight of 16
women who died (Table 2). One death attributed to
severe anaemia may have been drug-related or exacer-
bated but further details around the cause of death were
not available. For one woman, the causes of death were
unknown. Zidovudine was switched to stavudine 9
months after HAART initiation because of a persistent
severe neutropenia. About 16 months initiating stavu-
dine, she presented myalgia and received an analgesic. An
appointment was given to her 10 days later but she did
not come. She died at home one month later.
Factors associated with the of severe adverse events
In a multivariate Cox regression analysis, none of the fac-
tors investigated (age, previous exposure to PMTCT regi-
men, BMI, hemoglobin and neutrophil at baseline, and
HAART initiation during pregnancy) was statistically
associated with the first occurrence incidence of SAEs (n
= 88) after adjusting for CD4 cell count and WHO clinical
stage at enrollment (Table 3). When restricting the analy-
ses to severe hepatotoxicity, only ALT ≥31 UI/L was asso-
ciated with these SAEs (Table 3). The result did not
change when using combined outcomes: rash or severe
hepatotoxicity (data not shown). Similarly, when restrict-
ing the analyses to anaemia and/or neutropenia, only low
baseline neutrophil count <1500/mm3 was associated
with these SAEs (Table 3). Analysis with on treatment
approach led to similar results (data not shown).
Discussion
In Abidjan, Côte d'Ivoire, we followed 290 HIV-infected
women who started ZDV/3TC/NVP in combination with
co-trimoxazole. During a median follow-up on HAART
of 25 months, we observed a relatively high incidence rate
of SAEs of 19.5/100 patient-years. The risk factors identi-
fied for developing a SAE were elevated baseline transam-
inase levels for the occurrence of a rash and/or
hepatotoxicity and low baseline neutrophil count for
anaemia and/or neutropenia.
This high incidence rate of SAEs observed in our study
was due to the high incidence of grade ¾ neutropenia
(13.3/100 PY), probably due to the association ZDV and
co-trimoxazole. Approximately 90% (53/60) of grade ¾
neutropenia disappeared after the interruption of co-tri-
moxazole and only seven women had to stop ZDV owing
to neutropenia. This result is consistent with a study con-
ducted in Côte d'Ivoire where the 118 patients with inci-
dent grade ¾ neutropenia were all receiving co-
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trimoxazole when the neutropenia was detected. After
the interruption of co-trimaxazole, 73% of these SAEs
disappeared [21]. The incidence rate of anaemia esti-
mated in our study is also consistent with this study con-
ducted in Côte d'Ivoire and other studies in Africa [21-
23].
Concerning cutaneous rash or hepatotoxicity, most
reports have expressed the risk of SAEs using a cruder
indicator, the cumulative frequency. We estimated that
the cumulative frequencies of grade ¾ cutaneous rash
and hepatotoxicity were 5.2% et 3.4%, respectively. This
result is consistent with other studies realized in
resource-limited settings which have found frequencies
of grade ¾ rash ranging between 2.4% and 4.6% [13-
16,24] and grade ¾ hepatotoxicity ranging between 1.5%
and 6.6% [12-16]. The frequency of severe hepatotoxicity
is lower in resource-limited settings than in developed
countries where this frequency is between 5.8% and
17.6% [7,9,25-27]. This difference could be explained by a
different susceptibility to NVP between people from
resource-limited settings and Caucasian origin [28], a dif-
ferent distribution of the frequency of some risk factors
such as hepatitis B and C [27], drug use and alcohol con-
sumption. However, in the studies from resource-limited
settings, the frequency of these risk factors has not been
estimated. The other risks factors associated with the
hepatotoxicity and/or rash reported in litterature, such as
baseline HIV-1 RNA level, NVP plasma concentration,
Figure 1 Probability of occurrence of severe adverse events (grade ¾) and/or death in women initiating a nevirapine-based antiretroviral 
therapy in the MTCT-Plus program in Abidjan, Côte d'Ivoire 
Time of occurrence of first SAEs Month-3 Month-6 Month-12 Month-24 
Probability of SAEs occurrence (95% CI) 16.9 (13.1-21.9) 24.2 (19.5-29.7) 29.7 (24.6-35.6) 33.9 (28.4-40.2) 
No. of patients at risk 228 209 161 108 
Time of occurrence of death or SAEs Month-3 Month-6 Month-12 Month-24 
Probability of SAEs occurrence (95% CI) 17.3 (13.4-22.2) 24.4 (19.8-29.9) 31.3 (26.1-37.8) 37.8 (31.1-43.2) 
No. of patients at risk 226 197 160 99 
SAEs: severe adverse events 
CI: confidence interval 
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Table 2: Causes of death among HIV-infected women followed in the MTCT-Plus program and treated with NVP-based HAART.




Regimen* Cause of death Time of death** 
(months) 
History of SAEs Description of SAEs Time of 
occurrence of 
SAEs** (months) 
1 253 No AZT/3TC/NVP Mulitple myeloma 26.7 Yes Neutropenia grade 3 7.2
2 241 No AZT/3TC/NVP Hepatitis B 24.6 Yes Hepatotoxicity grade 3 24.2
3 332 No AZT/3TC/NVP Hepatitis B 13.3 Yes Anaemia grade 4 1.2
4 230 No AZT/3TC/NVP Unknown 24.9 Yes Neutropenia grade 4 9.2
5 271 Yes AZT/3TC/NVP Severe anaemia 3.7 Yes Anaemia grade 4 3.4
6 250 No AZT/3TC/NVP AIDS terminal 14.0 Yes Neutropenia Grade3 4.6
7 193 No AZT/3TC/NVP Cerebral malaria 20.8 Yes Rash grade 3 0.7
8 39 Yes AZT/3TC/NVP AIDS terminal 10.6 Yes Rash grade 3 2.0
9 170 Yes AZT/3TC/NVP AIDS terminal 20.4 No
10 186 Yes d4T/3TC/NVP Eclampsia 1.8 No
11 7 No AZT/3TC/NVP Pneumonia 6.9 No
12 226 No d4T/3TC/NVP Renal tumor 2.0 No
13 121 No AZT/3TC/NVP Cerebral malaria 10.0 No
14 84 Yes AZT/3TC/NVP Fever 9.8 No
15 24 No AZT/3TC/NVP Meningitis 7.4 No
16 288 Yes AZT/3TC/NVP Gastric perforation 12.9 No
* At initiation of treatment, SAEs = Severe adverse events grade III/IV
** After HAART initiation
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and genetic factors, could not be investigated in our study
because there are not recorded in routine circumstances
in Côte d'Ivoire.
In our cohort, a CD4 count >250 cells/mm3 was not
associated with occurrence of SAEs, including severe
hepatotoxicity and/or cutaneous rash, as was the case in
most studies conducted in resource-limited-settings [13-
16]. One study conducted in Mozambique among 146
pregnant women found a higher rate of severe hepatotox-
icity in women with CD4 >250 cells/mm3 (6.0% vs 0.0%; p
= 0.02) [12]. Generally in resource-limited-settings, a
great majority of HIV-infected patients initiate their
treatment late, generally when the CD4 cell count is
below 200 cells/mm3 [29,30]. In our study, the median
CD4 cell count was 188 cells/mm3 and only a few women
(30%) had a CD4 cell count above 250 cells/mm3. More-
over in this cohort, 47% of the women who had a CD4 cell
count ≤250 cells/mm3 initiated HAART during preg-
nancy, which may have resulted in an underestimation of
the CD4 count values due to physiological hemodilution
[31]. We also found that the initiation of HAART during
pregnancy was not associated with the occurrence of
Figure 2 Probability of occurrence of grade III/IV rash or hepatotoxicity during the three months of follow-up in women initiating a nevi-
rapine-based antiretroviral therapy according to the period of the initiation of treatment (pregnant and non pregnant women) . MTCT-Plus 
program in Abidjan, Côte d'Ivoire
HAART in non pregnant women HAART in pregnant women
Time of occurrence of SAEs Day 30 Day 90 Day 30 Day 90 
Probability of occurrence of SAEs 4.9 (2.5-9.6) 7.5 (4.3-12.7) 2.5 (0.8-7.5) 5.3 (2.1-12.2) 
No. of patients at risk 154 144 118 60 
SAEs: severe adverse events 
CI: confidence interval 
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Table 3: Factors associated with severe adverse events in women initiating NVP-based antiretroviral therapy.
All severe adverse events (N = 88)† Severe hepatotoxicity(N = 10) ZDV-related severe averse events (N = 71) 
HR 95% CI p HR 95% CI p HR 95% CI p 
Age (years)
≥30 (n = 137) 1.03 0.67-1.59 0.90 1.37 0.37-5.06 0.64 0.92 0.57-1.49 0.74
<30 (n = 153) 1.00 - - 1.00 - - 1.00 - -
Body mass index (Kg/m2) 
<18 (n = 40) 1.08 0.53-2.20 0.05 1.12 0.52-2.42 0.78
≥18 (n = 160) 1.00 - - 1.00 - -
CD4+ count/mm 3
>250 (n = 88) 0.68 0.41-1.12 0.14 1.75 0.48-6.39 0.40 0.64 0.36-1.14 0.13
≤250 (n = 202) 1.00 - - 1.00 - - 1.00 - -
WHO staging 
Stage 3 or 4 (n = 130) 1.00 0.63-1.58 0.99 1.31 0.36-4.74 0.68 1.07 0.65-1.79 0.77
Stage 1 or 2 (n = 160) 1.00 - - 1.00 - - 1.00 - -
ALT (IU/L) 
≥31(n = 50) 1.58 0.89-2.78 0.12 7.09 1.59-31.62 0.01 1.10 0.57-2.15 0.78
<31(n = 240) 1.00 - - 1.00 - - 1.00 - -
Neutrophil level (/mm3) 
<1500 (n = 28) 1.51 0.76-2.98 0.24 2.20 1.09-4.43 0.03 
≥1500 (n = 262) 1.00 - - 1.00 - -
Hemoglobin level (g/dL) 
≤9.8 (n = 150) 1.15 0.73-1.82 0.56 0.66 0.16-2.79 0.57 1.35 0.81-2.23 0.25
>9.8 (n = 140) 1.00 - - 1.00 - - 1.00 - -
Status of pregnancy 
Pregnant (n = 125) 0.98 0.60-1.64 0.98 1.22 0.22-6.62 0.82 1.11 0.65-1.91 0.70
Non pregnant (n = 165) 1.00 - - 1.00 - - 1.00 - -
Multivariable Cox regression analyses. MTCT-Plus program, Abidjan, Côte d'Ivoire (2003-2006).
HAART: Highly active antiretroviral therapy; WHO: World Health Organization; IQR: interquartile range; NVP: nevirapine; ALT: alanine aminotransferase; OR: odds ratio; aOR: adjusted odds ratio; 
CI: confidence interval, † If a woman had multiple severe adverse event
Coffie et al. BMC Infectious Diseases 2010, 10:188
http://www.biomedcentral.com/1471-2334/10/188
Page 9 of 10
severe rash or hepatotoxicity. We observed that the
median duration of follow-up of pregnant women was
relatively short (three months) but covered the higher-
risk period for occurrence of rash or hepatotoxicity.
When investigating the causes of death, we found that
half of these women (eight) had a history of SAEs during
their follow up and two cases can be associated with
medication toxicity: the woman who died after present-
ing grade 4 anaemia and those who died after presenting
myalgia. This could be due to lactic acidosis. For the
other deaths, it is difficult to attribute them to adverse
events because of the delay between the history of SAEs
and the time of death as well as the fact that documenting
cause of death in these settings is a real challenge. Further
pharmacovigilance studies should be conducted to docu-
ment the cause of death in relation to SAEs.
This study had two main limitations. First, the study
sample size was relatively small. This could reduce the
power to detect difference between the risk factor groups
and so the results should be interpreted with caution.
However, our results provided additional information on
the relation between CD4 counts >250 cells/mm3, preg-
nancy and severe adverse events. Few previous studies in
sub-Saharan Africa evaluated this association and did not
find any difference [13-16]. Second, we did not include
data on hepatitis B virus, hepatitis C, alcohol consump-
tion and drug use which are not routinely collected in
Cote d'Ivoire's national HIV program.
Overall, data reported in this MTCT-Plus cohort is
reassuring about the safety of NVP-based HAART in
routine circumstances. We did not observe severe events
such as Stevens-Johnson syndrome or Lyell syndrome,
and almost all the SAEs disappeared after discontinuation
of the incriminated drug.
Conclusion
This prospective cohort study provides additional data in
West Africa where CRF02 is the predominant of HIV-1
subtype and where the population was different. As
shown by almost all studies conducted in resource-lim-
ited settings, including our study, a high absolute CD4
cell count was not associated with a higher risk of severe
hepatotoxicity and/or rash, as well as pregnancy. How-
ever, as the sample size of these studies was limited, these
results should be interpreted with caution. Data on
women receiving NVP in resource-limited settings
remain limited and there is a pressing need for better
information about NVP toxicity in these settings. We
believe that further studies especially meta-analyze with
data available in low-income countries are urgently
needed. NVP-based HAART should continue to be used
with caution and close monitoring in eligible women for
HAART with absolute CD4 cell count between 250 and
350 cells/mm3 and in eligible pregnant women in
resource-limited settings if no other options exist.
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